D/E 4.68 — most levered decile in Healthcare (≈95th pctile)
P/E22.6xB+
P/E 22.6 — below the Healthcare median (≈40th pctile)
PEG1.63proxyC+
PEG 1.63 — modest premium; above fair value · PEG proxy: P/E ÷ revenue growth % (true PEG requires forward EPS estimates, not in Finnhub free tier).
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 70.4
Quality0.73
Growth0.84
Value0.57
Why this score
Durable high returns
Short track record
Entry · Margin of safety
52-week rangeNear 52-week high
3% off the 12-month high
vs DCF fair value7% aboveest. fair value ~$29
Quality signals · context only
ROIC65.0% · Areturn on invested capital — not score-weighted
Why now
Medical Care Facilities · market cap $4.0b. Trading near 52-week high of $32.35 — momentum setup, limited technical margin of safety. Revenue growing +14%, comfortably above the S&P median. 8 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $31.50 (implying +0% upside).
Moat
ROE 42% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 119% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
D/E 4.68 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Trading within 3% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction.
Horizon
1-3 yr $31.50 (8-analyst consensus) — fundamentals + valuation re-rating. 5 yr $46.12 at ~8% CAGR — compounding case rests on the competitive position widening. 10 yr $68.41 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Score history · CON
Trend
-1.6 over 14 daily scores
From 72.0 (Jun 22) → 70.4 (now)
One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Position sizing · CON
$
%
%
Shares to buy
63
Position size
$1,983
4.0% of portfolio
Stop price
$23.61
25% below $31.48
$ at risk if stopped
$495.81
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Concentra Group Holdings Parent, Inc. (CON): score, valuation & FAQ
Concentra Group Holdings Parent, Inc. (CON) is a Medical Care Facilities company that scores 70.4 out of 100 on the Bull Rankings quality-growth model — a solid, above-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are Rev (B+) and P/E (B+), while D/E (D) rate weaker. On valuation, CON sits about 7% above our discounted-cash-flow fair value (i.e. the DCF flags it as rich).
Is CON a good stock to buy?
Bull Rankings scores CON 70.4 out of 100 on its quality-growth model, which is a solid, above-average reading. That is driven by Rev (B+) and P/E (B+). A score is a quantitative screen of Concentra Group Holdings Parent, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does CON score 70.4 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). CON earns its highest marks on Rev (B+) and P/E (B+), and is held back by D/E (D). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is CON overvalued or undervalued?
Based on $31.48, CON sits about 7% above our discounted-cash-flow fair value (i.e. the DCF flags it as rich). It trades at a 22.6x× P/E (graded B+). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in CON?
D/E 4.68 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Trading within 3% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.